362 related articles for article (PubMed ID: 8459055)
41. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
42. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.
Merlini PA; Bauer KA; Oltrona L; Ardissino D; Spinola A; Cattaneo M; Broccolino M; Mannucci PM; Rosenberg RD
J Am Coll Cardiol; 1995 Jan; 25(1):203-9. PubMed ID: 7798503
[TBL] [Abstract][Full Text] [Related]
43. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
Merlini PA; Ardissino D; Rosenberg RD; Colombi E; Agricola P; Oltrona L; Ottani F; Galvani M; Bauer KA; Bottasso B; Bertocchi F; Mannucci PM
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2162-6. PubMed ID: 10978264
[TBL] [Abstract][Full Text] [Related]
44. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
Herren T; Straub PW; Haeberli A
Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
[TBL] [Abstract][Full Text] [Related]
45. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
46. Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.
Matsuo T; Koide M; Kario K
Artif Organs; 1997 Sep; 21(9):1035-8. PubMed ID: 9288875
[TBL] [Abstract][Full Text] [Related]
47. Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina.
Lidón RM; Théroux P; Robitaille D
Thromb Res; 1993 Oct; 72(1):23-32. PubMed ID: 8122184
[TBL] [Abstract][Full Text] [Related]
48. Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Matsuo T; Koide M; Kario K
Semin Thromb Hemost; 1997; 23(6):517-22. PubMed ID: 9469623
[TBL] [Abstract][Full Text] [Related]
49. Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Oldgren J; Siegbahn A; Grip L; Linder R; Thygesen K; Wallentin L
Thromb Haemost; 2004 Feb; 91(2):381-7. PubMed ID: 14961168
[TBL] [Abstract][Full Text] [Related]
50. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Jang IK; Gold HK; Ziskind AA; Leinbach RC; Fallon JT; Collen D
Circulation; 1990 Jan; 81(1):219-25. PubMed ID: 2297828
[TBL] [Abstract][Full Text] [Related]
51. Heparin-Induced Thrombocytopenia in Infants after Heart Surgery.
Abdillah JN; Hu Q; Chen X; Chen X; Zhou W; Luo W; Huang L
Thorac Cardiovasc Surg; 2019 Jan; 67(1):21-27. PubMed ID: 29605959
[TBL] [Abstract][Full Text] [Related]
52. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
[TBL] [Abstract][Full Text] [Related]
53. Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical and angiographic correlation.
Wilensky RL; Bourdillon PD; Vix VA; Zeller JA
J Am Coll Cardiol; 1993 Mar; 21(3):692-9. PubMed ID: 8436751
[TBL] [Abstract][Full Text] [Related]
54. Small-molecule direct antithrombins: argatroban.
Fareed J; Jeske WP
Best Pract Res Clin Haematol; 2004 Mar; 17(1):127-38. PubMed ID: 15171962
[TBL] [Abstract][Full Text] [Related]
55. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Lepor NE
Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
[TBL] [Abstract][Full Text] [Related]
56. Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits.
Hara H; Tamao Y; Kikumoto R; Okamoto S
Thromb Haemost; 1987 Apr; 57(2):165-70. PubMed ID: 3603410
[TBL] [Abstract][Full Text] [Related]
57. Increased number of thromboxane A2-prostaglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation.
Modesti PA; Colella A; Cecioni I; Costoli A; Biagini D; Migliorini A; Neri Serneri GG
Am Heart J; 1995 May; 129(5):873-9. PubMed ID: 7732975
[TBL] [Abstract][Full Text] [Related]
58. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
59. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Van Cott EM; Roberts AJ; Dager WE
Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
[TBL] [Abstract][Full Text] [Related]
60. Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy.
Urabe T; Tanaka R; Noda K; Mizuno Y
J Thromb Thrombolysis; 2002 Jun; 13(3):155-60. PubMed ID: 12355032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
